Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis

The novel ATP synthase inhibitor bedaquiline recently received accelerated approval for treatment of multidrug-resistant tuberculosis and is currently being studied as a component of novel treatment-shortening regimens for drug-susceptible and multidrug-resistant tuberculosis. In a limited number of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Almeida, Deepak, Ioerger, Thomas, Tyagi, Sandeep, Li, Si-Yang, Mdluli, Khisimuzi, Andries, Koen, Grosset, Jacques, Sacchettini, Jim, Nuermberger, Eric
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2016
Assuntos:
Mechanisms of Resistance
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4958187/
https://ncbi.nlm.nih.gov/pubmed/27185800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00753-16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados